(InSilico Medicine, Inc.) Insilico Medicine announced a research collaboration agreement with A2A Pharmaceuticals, Inc. The two parties agreed to create a new company called 'Consortium.AI', which will apply the latest advances in AI to discovery of novel small molecules for the Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases.
from EurekAlert! - Social and Behavioral Science https://ift.tt/2uyxQSO
No comments:
Post a Comment